dialysis and after transplantation. [7] [8] [9] [10] Two US and 2 European studies have shown that kidney transplantation (KT) improves survival among elderly patients. 1, [11] [12] [13] Moreover, the improved quality of life observed after KT favors this option whenever it is possible.
14,15
Many of these elderly ESRD patients have obvious and recognized contraindications to KT: active malignancy, cardiovascular or respiratory comorbidities, senile dementia, or refusal by a fully informed patient. 16 Among other patients, nephrologists must evaluate who may benefit from KT. Current guidelines and recommendations state that advanced age per se is not a contraindication to KT and that chronologic age is less important than physiologic age and comorbidity severity. [16] [17] [18] [19] [20] [21] Nephrologists remain divided, however, about placing elderly patients on KT waiting lists, [22] [23] [24] probably because increasing age and age-related comorbidities are recognized major and independent risk factors for death after transplantation, especially in the perioperative period. 7, 8, [25] [26] [27] Consequently, older patients still have poor access to KT, and age remains a factor associated with nonplacement on the waiting list. 28, 29 In France, between 2002 and 2011, the cumulative incidence rate of access to transplantation for patients younger than 60 years was 57% at 5 years, compared to only 1.5% for those ≥70 years. The percentage of prevalent dialysis patients aged 75 to 84 years who received a KT in Europe ranged from 0% to 4%, depending on the country. 28 Only 3.4% of US ESRD patients aged ≥70 were on a waiting list. 30 Thus, this study aimed to inform and help decision-making about KT for the elderly by evaluating its mortality risk and survival benefits after surgery and identifying risk factors for posttransplant mortality among a cohort of patients from metropolitan France who began RRT at age ≥70. Previous studies of KT survival benefit in the elderly have taken place either in younger populations 12, 13 or in countries where survival on dialysis is lower than in France.
1, 11, 31, 32 The risk of mortality in transplant patients was first compared to that of patients on the waiting list but not transplanted and then to that of matched dialysis patients.
| MATERIAL S AND ME THODS

| Study population and data sources
We used data collected from the French Renal Epidemiology and Information Network (REIN) registry. The REIN registry is intended to include all ESRD patients on RRT-either dialysis or transplantation-living in France, including the overseas districts. After beginning in 2002 and progressively expanding, it has included the entire country since 2011 and covers 100% of the ESRD patient population in each region. The details of its organizational principles and quality control have been described elsewhere. 33 Clinical data are recorded when RRT begins and annually thereafter by the attending nephrologist, and their accuracy is verified by REIN research assistants.
Events such as death, wait-listing (regardless of donor type, ie, living and/or deceased), and KT are prospectively recorded on occurrence.
The population studied here comprised all patients in the REIN 
| Statistical analysis
Continuous variables are reported as means (standard deviation, SD) and categorical variables as percentages.
The survival benefit of KT was assessed by comparison first with a cohort restricted to patients on the waiting list and then with the matched cohort of dialysis patients, by using Cox regression models with KT as a time-dependent variable. This model accounts for immortal time in transplant patients 35, 36 and deals with the variation of the transplant effect over time. For the cohort of waiting-list patients, follow-up started on the date of either placement on the waiting list or RRT initiation, whichever came later. In the matched cohort of dialysis patients, follow-up started with RRT and Cox regression models were stratified by pairs to take data matching into account.
In both cases, patients had their data censored for end of follow-up period (December 31, 2014) or the last date they were known to be alive, whichever came first.
Because mortality risk varies with time since KT, hazard ratios for mortality after KT were estimated at different points: every 3 months in the first-year posttransplant and yearly for the next 2 years. Hazard ratios (HRs) of mortality change after KT were also depicted with cubic spline functions (SAS-Macro RCS).
Complementary analyses were performed, stratified by the presence of cardiovascular comorbidities or diabetes. Separate analyses were also done for patients with preemptive and nonpreemptive KT, by censoring the follow-up of the other subgroup at the time of transplantation.
To identify risk factors for posttransplant mortality, survival was defined as the time from transplantation to death and analyzed with Cox regression models. All potential risk factors for death after transplantation and confounders were introduced in the multivariate analysis and then selected by a stepwise backward procedure.
All tests were 2-sided and P < .05 was considered statistically significant. Analyses were performed with SAS guide 7.1 (SAS Institute, Inc). 
| RE SULTS
| Global description of the cohort
| Patient characteristics at RRT initiation
Compared to wait-listed patients who were selected for better health, dialysis patients not on the waiting list at the end of the study were on average 6.5 years older, had diabetes 1.5 times more often, were almost 4 times more likely to have 2 or more cardiovascular comorbidities, 2.6 times more likely to have an active malignancy, and 2.2 times more likely to have a chronic respiratory disease at RRT initiation.
Neurologic complications and disability (blindness, severe behavioral disorders, and loss of autonomy for transfer) appeared to be exclusion criteria from the waiting list; in any case, it included only a few patients with these problems. Among patients not placed on the waiting list, 20% had neither cardiovascular comorbidity nor diabetes.
Compared to patients still on dialysis at the end of the study, transplant patients were younger and less likely to have diabetes, cardiovascular comorbidities, chronic respiratory disease, or an active malignancy on starting RRT (Table 1) . Only a few of them needed assistance for transfer, whereas more than a quarter of dialysis patients did. The prevalence of diabetes, cardiovascular comorbidities, and active malignancy at RRT initiation remained lower in transplant patients than in dialysis patients on the waiting list. Half (49.4%) the transplant patients had neither diabetes nor cardiovascular comorbidity, whereas this was true of only 36.5%
of the nontransplant wait-listed patients and 20.2% of the nontransplant dialysis patients. 
| Mortality risk after KT compared to patients on the waiting list
| Mortality risk after KT compared to matched dialysis patients
Analysis of the matched datasets showed mortality rates of 17.3% 
| Risk factors for mortality after transplantation
After adjustment for recipient and donor characteristics, independent risk factors for mortality after transplantation were diabetes, at least one cardiovascular comorbidity, and a pretransplant dialysis duration exceeding 2 years ( 
| D ISCUSS I ON
To our knowledge this is the largest European study of patients who began RRT at age ≥70. It compared the mortality risk of transplant patients first with that of patients remaining on the waiting list and then to that of dialysis patients with similar characteristics.
Transplant patients had a risk of death by the end of month 3 triple that of waitlisted patients. By month 9, this risk had fallen to half that of patients still on the waiting list. The comparison with a cohort of dialysis patients matched for clinical characteristics showed KT was associated with a reduction of mortality risk by the end of month 3 and no significant increase in risk during the perioperative period.
During a mean follow-up period of 27 months, 2.9% of the patients who began RRT at age ≥70 were placed on the KT waiting list and 2.1% had transplants. The transplant patients were younger and had fewer comorbidities than patients still on dialysis when fol- TA B L E 1 (Continued) TA B L E 2 Unadjusted death rates and association, after imputation, between mortality risk and kidney transplantation, in patients placed on the waiting list, with Cox models taking time since transplantation into account Model 1: Unadjusted. Model 2: Adjusted for gender, age, number of cardiovascular comorbidities (congestive heart failure, coronary vascular disease/myocardial infarction, dysrhythmia, cerebrovascular disease, and peripheral vascular disease), mobility status, diabetes, and time on dialysis at inclusion.
type varied markedly. In the 30% of transplants from expanded criteria donors, the initial increase in the risk of death ranged from 2 to 2.7 and the number of days to equal risk from 95 to 180, depending on the recipient's cardiovascular risk group. In the current study, where 92% of transplants came from expanded criteria donors, the initial increase in the risk of death and the time to equal risk of transplant and wait-listed patients were not far from the figures in Gill's study for transplants from expanded criteria donors. However, the decrease in mortality risk due to KT after the first year was lower in our study than in previous reports, and the initial risk due to surgery was not offset by a sufficient survival benefit at M36. Several explanations for these discordant data can be proposed.
First, the lack of a patient survival benefit observed in transplant compared with wait-listed patients may be due to poorer survival in transplant recipients because of higher donor age. Several studies have shown that KT to elderly patients with older (thus poorer quality) grafts nonetheless provides better survival than chronic dialysis does. found that the survival benefit was no longer significant in recipients aged ≥70. 43 The transplant patients in our study had a death rate of 6.4 per 100 patient years, compared to 13.2 in the study by Rao et al (for deceased donor recipients) and from 10 to 16 in the study by Gill et al, depending on recipient cardiovascular risk. Posttransplant mortality in the current study was therefore not higher than in previous studies despite the more frequent use of expanded criteria donors and older donors.
Another explanation may be better survival in nontransplant patients in this compared to previous studies, either because of better survival on dialysis, as suggested by other studies comparing mortality in hemodialysis patients between different countries, 31, 32 or because of more rigorous selection of patients on the waiting list in
France than in the United States. In the study we report here, more than half the patients placed on the waiting list (55%) did not have either diabetes or any cardiovascular comorbidity, and the death rate among those remaining on the waiting list was less than 10 per 100 patient-years. The death rate for wait-listed patients in the study by Sometimes patients themselves refuse placement on the waiting list, as 5% of dialysis patients older than 70 years in France do.
44
Nonetheless, transplantation has been shown to improve the quality of life significantly, even in the elderly.
14,15
Because 92% of the grafts in this study came from expanded criteria donors, the only risk factors for mortality after transplantation were recipient characteristics, specifically, diabetes, at least one cardiovascular comorbidity, and pretransplant dialysis F I G U R E 2 Adjusted* hazard ratios of mortality (95% CI), after imputation, months after kidney transplantation, transplant vs patients remaining on the waiting list, according to comorbidities at inclusion. *Adjustment for gender and age, mobility status, and time on dialysis at inclusion F I G U R E 3 Adjusted* hazard ratios of mortality (95% CI), after imputation, months after kidney transplantation, transplant vs patients remaining on the waiting list, according to time of transplantation (preemptive vs others). *Adjustment for gender and age, number of cardiovascular comorbidities (congestive heart failure, coronary vascular disease/myocardial infarction, dysrhythmia, cerebrovascular disease, and peripheral vascular disease), mobility status, and diabetes duration longer than 2 years. The risk of early mortality after transplantation, compared with matched dialysis patients, was lower in patients with preemptive transplantation and those without cardiovascular comorbidity or diabetes. As reported previously, the most common causes of posttransplant deaths, after infectious diseases and malignancies, were cardiovascular diseases.
25,28
Cardiovascular comorbidities should therefore continue to be a criterion for waiting-list selection. Recent recommendations from the European Renal Association -European Dialysis and Transplant Association state that comorbidity, frailty, and psychosocial assessments should be used to help make these eligibility decisions. 20 Clinical scores based on posttransplant mortality risk factors have also been developed to identify patients suitable for transplantation.
7,48
Compared with the matched dialysis patients, the subgroups of patients with preemptive KT and with KT and neither cardiovascular comorbidity nor diabetes had a lower risk of early posttransplant mortality. This decrease was not observed when these 2 subgroups of transplant patients were compared with patients on the waiting list. This result, however, may be explained by the relatively small number of patients placed on the waiting list, which decreased the study power, especially in the subgroup analysis.
In the context of organ shortage, transplanting elderly people rather than young people can be questioned. In France in 2016, 35% of donation after brain death (DBD) donors from whom at least one kidney was transplanted were over 65 years old, 27% were ≥70%, and 19% were ≥75. Because of the need to match the functional capacity of organs to the recipients' functional requirements, many TA B L E 3 Unadjusted death rates and association, after imputation, between mortality risk and kidney transplantation, in a matched cohort a of patients on RRT, Cox models stratified by pairs, and taking time since transplantation into account probably always be difficult to determine the long-term benefits of kidney transplantation in this population.
| CON CLUS ION
In this large French nationwide study of patients beginning RRT at age ≥70, only 2.9% of the overall group were on the waiting list, and 72% of them were transplanted. Twenty percent of the patients not placed on the waiting list did not have any cardiovascular comorbidity or diabetes. In contrast to previously published studies, KT did not provide any clear survival benefit, compared with the patients who are remaining on the waiting list. However, when compared with matched dialysis patients not on the waiting list, who had a longer follow-up, the benefit of transplantation was obvious. Risk factors for posttransplant mortality were diabetes, at least one cardiovascular comorbidity, and time on dialysis exceeding 2 years.
In addition to the benefits of transplantation in improving the quality of life, preserving autonomy, and reducing the medicoeconomic impact of patients with ESRD, these results led us to recommend the systematic evaluation of all elderly patients for transplantation eligibility and to inform all eligible patients about the possibility of KT, so that they can all have the choice to stay on dialysis or to be placed on the waiting list. This assessment should take into account their comorbidities, frailty index, and the balance between the expected benefit and the risk of early death, about which the patient must be informed. This evaluation should be conducted as early as possible to limit the duration of dialysis or enable a preemptive KT. Recent national recommendations on access to the waiting list should improve access to KT for elderly patients. Further studies will be needed to evaluate the results after these recommendations are implemented.
ACK N OWLED G M ENTS
We gratefully acknowledge all registry participants, especially the nephrologists and the professionals who collected the data and conducted the quality control. The centers participating in the registry are listed in the REIN annual report: https://www.agence-biomedecine.fr/Le-programme-REIN.
D I SCLOS U R E
The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation. 
R E FE R E N C E S
